Effect of resveratrol on microcirculation disorder and lung injury following severe acute pancreatitis in rats.
OBJECTIVE
To investigate the mechanism of resveratrol underlying the microcirculation disorder and lung injury following severe acute pancreatitis (SAP).


METHODS
Twenty-four rats were divided into 3 groups (SAP, sham and resveratrol groups) randomly. SAP model was established by injecting 4% sodium taurocholate 1 mL/kg through puncturing pancreatic ducts. Sham (control) group (8 rats) was established by turning over the duodenum. Resveratrol was given at 0.1 mg/kg b.m. intraperitoneally. Rats were sacrificed 9 h after SAP was induced. Blood samples were obtained for hemorrheological examination. Lung tissues were used for pathological observation, and examination of microvascular permeability, dry/wet ratio and myeloperoxidase (MPO) activity. Gene expression of intercellular adhesion molecule-1 (ICAM-1) was detected by RT-PCR.


RESULTS
Compared with SAP group, resveratrol relieved the edema and infiltration of leukocytes in the lungs. Resveratrol improved markers of hemorrheology: high VTB (5.77+/-1.18 mPas vs 9.49+/-1.34 mPas), low VTB (16.12+/-3.20 mPas vs 30.91+/-7.28 mPas), PV (4.69+/-1.68 mPas vs 8.00+/-1.34 mPas), BSR (1.25+/-0.42 mm/h vs 0.03+/-0.03 mm/h), VPC (54.67+/-3.08% vs 62.17+/-3.39%), fibrinogen (203.2+/-87.8 g/ L vs 51.3+/-19.1 g/L), original hemolysis (0.45+/-0.02 vs 0.49+/-0.02), and complete hemolysis (0.41+/-0.02 vs 0.43+/-0.02) (P<0.05). Resveratrol decreased the OD ratio of ICAM-1 gene (0.800+/-0.03 vs 1.188+/-0.10), dry/wet ratio (0.74+/-0.02 vs 0.77+/-0.03), microvascular permeability (0.079+/-0.006 vs 0.112+/-0.004) and MPO activity (4.42+/-0.32 vs 5.03+/-0.51) significantly (P<0.05).


CONCLUSIONS
Resveratrol can improve the microcirculation disorder of the lung by decreasing leukocyte-endothelial interaction, reducing blood viscosity, improving the decrease of blood flow, and stabilizing erythrocytes in SAP rats. It may be a potential candidate to treat SAP and its severe complications (ALI).
Meng
Yong
Y
Department of Hepatobiliary Surgery, First Hospital, Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. my176@sohu.com
Zhang
Mei
M
Xu
Jun
J
Liu
Xue-Min
XM
Ma
Qing-Yong
QY
D000208:Acute Disease; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D010195:Pancreatitis / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D011652:Pulmonary Circulation / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013267:Stilbenes; D000077185:Resveratrol